Alzheimer's drugs, APPlication for Down syndrome?
Deborah K Sokol1, Debomoy K Lahiri2
1Department of Neurology, Section Pediatrics, Indiana University of Medicine, Riley Hospital, 575 Riley Hospital Drive, Indianapolis, IN 46202, USA.
Ageing Research Reviews
|March 21, 2024
Summary
Down syndrome (DS) and Alzheimer's disease (AD) share similarities, including amyloid-beta (Aβ) accumulation. New Aβ-clearing antibody therapies may offer treatment options for cognitive impairment in individuals with DS.
Area of Science:
- Neurology
- Genetics
- Pharmacology
Background:
- Down syndrome (DS) is characterized by amyloid-beta (Aβ) peptide accumulation.
- Individuals with DS often develop dementia resembling Alzheimer's disease (AD).
- Current treatments for AD in DS are limited.
Purpose of the Study:
- To explore the similarities between DS and AD in adult subjects.
- To discuss challenges in targeting amyloid precursor protein (APP) metabolites.
- To investigate the potential of new Aβ-targeting antibody therapies for AD in DS.
Main Methods:
- Comparative analysis of DS and AD pathologies.
- Review of existing and emerging drug therapies for AD.
- Discussion of challenges in targeting APP metabolites.
Main Results:
- Significant pathological overlap exists between AD and dementia in adult DS.
- New monoclonal antibody therapies show promise in clearing Aβ plaques.
- Targeting Aβ presents a viable therapeutic strategy.
Conclusions:
- Individuals with DS experiencing cognitive decline may benefit from Aβ-clearing therapies.
- Further investigation into antibody treatments for AD in DS is warranted.
- Early intervention strategies targeting Aβ could be beneficial.
More Related Videos
10:02Assessment of Spontaneous Alternation, Novel Object Recognition and Limb Clasping in Transgenic Mouse Models of Amyloid-β and Tau Neuropathology
Published on: May 28, 2017
26.8K
06:38In Vitro Modeling of Down Syndrome Neurogenesis Using Human-Induced Pluripotent Stem Cells
Published on: March 7, 2025
414
Related Concept Videos
01:22Alzheimer's Disease: Treatment
184
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
184
01:26Alzheimer's Disease: Overview
469
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
469
01:30Dementia
113
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
113
01:24Parkinson's Disease: Treatment
264
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
264
01:15Parkinson's Disease: Overview
541
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
541
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
122
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
122